Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES SCLC).

@inproceedings{Schneider2010PhaseIT,
  title={Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES SCLC).},
  author={Bryan J. Schneider and Shirish M. Gadgeel and Nithya Ramnath and Antoinette J. Wozniak and Grace Kho Dy and Stephanie D Daignault and Gregory P. Kalemkerian},
  year={2010}
}
e18041 Background: The prognosis for patients (pts) with ES SCLC is poor, with a median progression-free (PFS) and overall survival (OS) of 5 mo. and 9 mo., respectively. This trial was designed to evaluate the efficacy/toxicity of maintenance sunitinib after platinum-based chemotherapy in pts with ES SCLC. Methods: Treatment consisted of cisplatin 75 mg/m2 IV or carboplatin AUC 5 on day 1 plus etoposide 100 mg/m2 IV on days 1-3 every 21 days for 4 cycles. If no evidence of disease progression… CONTINUE READING